10-Q: ALX Oncology Q3 2025: Pipeline Progress, Financial Losses

ALX Oncology reports a Q3 2025 net loss of $22.1 million, advancing evorpacept and ALX2004 programs while managing significant cash burn and facing regulatory setbacks.

Summary

• Net loss for the three months ended September 30, 2025, was $22.1 million, an improvement from $30.7 million for the same period in 2024.
• Net loss for the nine months ended September 30, 2025, was $78.8 million, down from $105.7 million for the same period in 2024.
• Cash, cash equivalents, and investments totaled $66.5 million as of September 30, 2025, a decrease from $131.3 million as of December 31, 2024.
• Research and development (R&D) expenses decreased by 34% to $17.4 million for Q3 2025 and by 36% to $59.3 million for the nine months ended September 30, 2025, driven by completed clinical trial material manufacturing, workforce reduction, and pipeline prioritization.
• General and administrative (G&A) expenses decreased by 16% to $5.1 million for Q3 2025 and by 3% to $18.5 million for the nine months ended September 30, 2025, primarily due to reduced stock-based compensation and legal consulting costs, partially offset by severance.
• An impairment charge of $3.2 million was recognized for the nine months ended September 30, 2025, related to the decision to sublease a Palo Alto property.
• Evorpacept, a CD47 blocker, is being evaluated in the Phase 2 ASPEN-Breast clinical trial for HER2-positive metastatic breast cancer, with the study amended to a single-arm design evaluated by CD47 expression.
• ALX2004, a novel EGFR-targeted antibody-drug conjugate (ADC), entered a Phase 1 clinical trial in August 2025.
• Exploratory analysis from the ASPEN-06 trial in gastric cancer identified CD47 overexpression as a key predictive biomarker for response and durable benefit, showing a 65.0% objective response rate (ORR) and 25.5 months median duration of response (mDOR) in CD47-high patients.
• The FDA determined that ASPEN-06 Phase 2 data was not eligible for accelerated approval, requiring a Phase 3 trial against ENHERTU, which the company will not pursue independently for gastric cancer.
• The ASPEN-CRC study for colorectal cancer was paused to focus resources on the ASPEN-Breast trial.
• Existing capital resources are believed to be sufficient to fund projected operating requirements into the first quarter of 2027.
• The company regained compliance with the Nasdaq minimum bid price requirement in September 2025.

Sentiment

Score: 3

Explanation: While the company reported reduced net losses and some positive exploratory clinical data for evorpacept in CD47-high gastric cancer, significant negatives include the FDA's decision against accelerated approval for ASPEN-06 in gastric cancer (leading to the company not pursuing it independently), the pausing of another clinical program (ASPEN-CRC), and a substantial decrease in cash reserves, indicating ongoing high cash burn and a clear need for future capital raises. The overall outlook remains highly uncertain with major development programs facing setbacks or being streamlined.

Positives

• Net loss decreased to $22.1 million for Q3 2025 from $30.7 million in Q3 2024, and to $78.8 million for the nine months ended September 30, 2025, from $105.7 million in the prior year period.
• Research and development expenses decreased significantly by 34% for Q3 2025 and 36% for the nine months ended September 30, 2025, reflecting pipeline prioritization and cost management.
• General and administrative expenses decreased by 16% for Q3 2025 and 3% for the nine months ended September 30, 2025.
• Positive pre-planned exploratory analysis from the ASPEN-06 clinical trial in gastric cancer identified CD47 overexpression as a key predictive biomarker for response and durable benefit, with Evo-TRP showing a 65.0% ORR and 25.5 months mDOR in CD47-high patients.
• ALX2004, a novel EGFR-targeted ADC, successfully initiated its first-in-human Phase 1 clinical trial in August 2025.
• The company regained compliance with the Nasdaq minimum bid price requirement in September 2025.
• Existing capital resources are projected to fund operating expenses and capital expenditure requirements into the first quarter of 2027.

Negatives

• The company continues to incur significant net losses, with an accumulated deficit of $700.0 million as of September 30, 2025.
• Cash, cash equivalents, and investments decreased substantially from $131.3 million at December 31, 2024, to $66.5 million at September 30, 2025, indicating a high cash burn rate.
• The FDA determined that ASPEN-06 Phase 2 data for gastric cancer was not eligible for accelerated approval, requiring a Phase 3 trial against ENHERTU, which the company will not pursue independently, effectively halting its U.S. registrational path for this indication.
• The ASPEN-CRC study for colorectal cancer was paused, narrowing the company's clinical pipeline focus.
• An impairment charge of $3.2 million was recognized for the nine months ended September 30, 2025, due to the decision to sublease a property.
• Interest income decreased significantly by 65% for Q3 2025 and 55% for the nine months ended September 30, 2025, primarily due to lower cash and investment balances.
• Previous Phase 2 ASPEN-03 and ASPEN-04 clinical trials did not meet primary endpoints, leading to the discontinuation of evorpacept in head and neck squamous cell carcinoma (HNSCC).

Risks

• Incurred significant net losses since inception and expects to continue incurring significant net losses for the foreseeable future.
• Requires substantial additional capital to finance operations, which may not be available when needed or only on unfavorable terms.
• Limited operating history, no products approved for commercial sale, and no revenue from product sales, licenses, or collaborations.
• Substantially dependent on the success of lead product candidate, evorpacept, and second product candidate, ALX2004, both in clinical development and not having completed pivotal trials.
• Outcome of preclinical testing and early clinical trials may not be predictive of success in later clinical trials, and results may not satisfy regulatory requirements.
• Clinical trials are expensive, time-consuming, difficult to design and implement, and may fail to demonstrate adequate safety, efficacy, and potency.
• Product candidates may cause significant adverse events or undesirable side effects.
• Regulatory approval processes are lengthy, time-consuming, and inherently unpredictable.
• Inability to obtain, maintain, and enforce patent protection and other intellectual property could materially harm the business.
• Highly dependent on key personnel; failure to attract, motivate, and retain qualified personnel could hinder business strategy.
• Relies on third-party manufacturers for clinical supplies, increasing risk of insufficient quantities, unacceptable cost, or quality issues.
• Debt levels and compliance with loan agreement terms could restrict business operations and lead to default.
• Macroeconomic conditions and global economic environment (inflation, interest rate changes, trade disputes, economic downturns, bank failures, geopolitical risks, public health crises) could adversely impact business and clinical trials.
• Stock price may be volatile, leading to potential loss of investment.
• Past material weaknesses in internal control over financial reporting; inability to maintain effective controls could harm financial reports and stock price.
• Delays or difficulties in subject enrollment and retention in clinical trials.
• Interim, topline, and preliminary data may change.
• Failure to achieve market acceptance for approved products.
• Competition from other companies developing similar or different immuno-oncology therapies.
• Significant post-marketing regulatory requirements and oversight for approved products.
• Reliance on third-party service providers for preclinical research activities and potential disruptions if unable to transition in-house or find alternatives.
• Material modifications in manufacturing or formulation may result in additional costs or delays.
• Development of product candidates in combination with other therapies exposes to additional risks (e.g., revocation of approval for combination therapy, supply issues, prohibitive costs).
• Failure to obtain or maintain adequate coverage and reimbursement for products.
• FDA and other regulatory agencies actively enforce laws prohibiting off-label uses.
• Changes in patent laws or jurisprudence could diminish patent value.
• Inability to protect intellectual property rights throughout the world.
• Patent terms may be inadequate.
• Dependence on third parties for patent protection, prosecution, assertion, and defense.
• Inability to protect confidentiality of trade secrets.
• Lawsuits to protect or enforce patents and trade secrets.
• Claims of wrongful use or disclosure of trade secrets from former employers.
• Intellectual property rights may not provide competitive advantages.
• Need for FDA approval for product candidate names.
• Rights to develop and commercialize products may be subject to third-party agreements.
• Difficulties in managing organizational growth.
• Product candidates based on novel technology, making development time and cost difficult to predict.
• International operations expose to business, regulatory, political, operational, financial, pricing, and reimbursement risks.
• System failures or security breaches could cause disruptions or financial damages.
• Disclosure controls and procedures may not prevent or detect all errors or fraud.
• Securities litigation.
• Dependence on subsidiaries' cash flows.
• Business disruptions (natural disasters, public health crises, geopolitical unrest).
• Market conditions could impair access to cash and investments.
• No anticipation of paying cash dividends.
• Delaware law and charter provisions might discourage change in control.
• Exclusive forum provisions in bylaws.

Future Outlook

The company expects to continue incurring significant expenses and increasing operating losses for the foreseeable future. Existing cash, cash equivalents, and investments are projected to fund operating expenses and capital expenditure requirements into the first quarter of 2027. The company plans to advance evorpacept through multiple clinical trials in various indications, pursue regulatory approval, and progress ALX2004 through its first-in-human trial. Additional funding will be required to fully implement its business plan, which may be sought through equity offerings, debt financings, collaborations, or strategic alliances.

Management Comments

• We believe that the existing capital resources will be sufficient to fund the projected operating requirements for at least the next twelve months after the date the condensed consolidated financial statements are issued.
• Management recognizes the need to raise additional capital to fully implement its business plan.
• We expect our expenses to increase substantially in connection with our ongoing activities, particularly as we advance the preclinical activities and clinical trials for our product candidates in development.
• We believe our existing cash, cash equivalents and investments will enable us to fund our operating expenses and capital expenditure requirements into the first quarter of 2027.

Industry Context

The company operates in the highly competitive clinical-stage biotechnology and immuno-oncology sectors, focusing on novel therapies for cancer by targeting pathways like CD47 and EGFR. The industry is characterized by lengthy, expensive, and uncertain drug development processes, intense competition from established pharmaceutical and biotechnology companies, and evolving regulatory landscapes. Recent FDA initiatives (e.g., Project Optimus, Project FrontRunner) and judicial decisions (e.g., overturning of the Chevron doctrine) introduce further complexities and potential delays in regulatory approvals. Additionally, governmental efforts to control healthcare costs, such as the Inflation Reduction Act, are creating pricing pressures and impacting reimbursement for new drugs, posing challenges for commercialization.

Comparison to Industry Standards

• The company faces substantial competition in the CD47 pathway space from numerous developers including Adagene, Akesobio, Bio-Thera Solutions, Boehringer Ingelheim, Bristol Myers Squibb, Byondis, Centessa, Conjupro Biotherapeutics, CTTQ (SinoBiological), Daiichi Sankyo, Exelixis, GenSci, Gilead Sciences (through its acquisition of Forty Seven), Hanchor Bio, Hisun, Hutchmed, I-Mab, Ichnos, ImmuneOncia Therapeutics, ImmuneOnco Biopharma, Innovent, Kahr, LaNova, Lightchain Bioscience, Mabwell Therapeutics, Mabworks, Novimmune, OSE Immunotherapeutics, Pfizer (through its acquisition of Trillium Therapeutics), Phanes, Pyxis Oncology (through its acquisition of Apexigen), Shandong New Time, Shattuck Labs, Sorrento Therapeutics, Sumgen, SunHo Pharmaceutical, TG Therapeutics, Waterstone, and Zai Lab.
• In the EGFR-targeted ADC field, the company competes with developers such as AstraZeneca, BioNTech, Bristol Myers Squibb with Systimmune, CSPC, and Henlius.
• The FDA's preference for randomized controlled trials for accelerated approval, as outlined in recent draft guidance, impacts the company's single-arm ASPEN-Breast study, potentially requiring additional data or trials.
• The decision not to pursue a U.S. registrational path with a Phase 3 trial for evorpacept in gastric cancer, following FDA guidance that Phase 2 data was not eligible for accelerated approval, highlights the high bar for market entry and the competitive pressure from existing therapies like ENHERTU.

Management Changes

Legal Proceedings

• Not currently a party to any material legal proceedings.
• No pending or threatened litigation as of September 30, 2025.

Related Party Transactions

• Tallac Therapeutics, Inc.: The Tallac Services Agreement, under which Tallac provided preclinical research services, terminated on July 1, 2024.
• Tallac Therapeutics, Inc.: R&D costs related to the Tallac Collaboration Agreement decreased from $0.7 million for the nine months ended September 30, 2024, to $0.1 million for the nine months ended September 30, 2025.

Stakeholder Impact

• Shareholders: Face potential for further dilution from future equity raises, continued stock price volatility due to clinical trial outcomes and financial performance, and must rely on share appreciation as no cash dividends are anticipated.
• Employees: Experienced a reduction in workforce in Q1 2025, which could lead to reduced morale and loss of institutional knowledge, and the company faces intense competition for attracting and retaining qualified personnel.
• Patients: May benefit from potential new cancer therapies (evorpacept, ALX2004) if development is successful, but delays or discontinuation of programs could limit future treatment options.
• Creditors: The company is in compliance with term loan covenants, with $25.0 million available at the lenders' discretion, but principal payments begin December 1, 2025.
• Suppliers/CROs: The company continues to rely on third-party manufacturers and CROs for development and manufacturing, indicating ongoing business relationships.

Next Steps

• Advance evorpacept through multiple clinical trials in various indications.
• Pursue regulatory approval of evorpacept in solid tumors and hematological malignancies.
• Advance ALX2004 through its first-in-human trial.
• Continue preclinical and clinical development efforts.
• Obtain and maintain patent, trade secret, and other intellectual property protection and regulatory exclusivity for product candidates.
• Manufacture supplies for preclinical studies and clinical trials.
• Add operational, financial, and management information systems to support ongoing operations as a public company.
• Consider exploring development partnerships to advance the gastric cancer program for evorpacept.
• Sanofi to continue the dose optimization portion of the UMBRELLA study for multiple myeloma.
• Present pre-planned exploratory analysis of the ASPEN-06 clinical trial in gastric cancer at the SITC Annual Meeting on November 8, 2025.
• Attend the hearing before the Board of Appeal for European Patent (EP 2 429 574) scheduled for December 9, 2025.
• Attend the opposition hearing for European Patent (EP 2 995 315) scheduled for November 28, 2025.
• Begin making principal payments on the term loan on December 1, 2025.

Key Dates

Recommendation

The company is at a critical clinical stage with both positive and negative developments. While there's promising exploratory data for evorpacept in gastric cancer (CD47-high patients) and ALX2004 has entered Phase 1, the FDA's decision against accelerated approval for ASPEN-06 and the company's choice not to pursue a Phase 3 independently for gastric cancer represent a significant setback for that indication. The pausing of ASPEN-CRC further narrows the pipeline focus. The substantial cash burn and projected funding into Q1 2027 indicate a clear need for future capital raises, which could lead to dilution. The reduced net loss is primarily due to decreased R&D spending and an impairment charge, rather than increased revenue. Given the mixed clinical news, high cash burn, and the need for future financing, a 'Hold' recommendation is appropriate for investors to monitor further clinical progress and financing strategies. The positive biomarker data in ASPEN-06 offers a glimmer of hope for evorpacept's potential in specific patient populations, but the path to market remains challenging and uncertain.

Keywords

ALX Oncology, biotechnology, oncology, cancer therapy, evorpacept, CD47 blocker, ALX2004, EGFR-targeted ADC, clinical trials, Phase 2, Phase 1, HER2-positive breast cancer, gastric cancer, GEJ cancer, Non-Hodgkin lymphoma, multiple myeloma, immuno-oncology, financial results, net loss, R&D expenses, cash burn, Nasdaq compliance, biomarker, CD47 overexpression, drug development, SEC filing, 10-Q